Irvine, United States
enVVeno Medical is a late clinical-stage medical device company, headquartered in Irvine, California, with a clear focus on addressing the unmet needs in the treatment of venous disease. The company's flagship product, the VenoValve®, a first-in-class implant designed for addressing deep venous Chronic Venous Insufficiency (CVI), has the potential to significantly improve the lives of the approximately 2.4 million affected individuals in the United States. The VenoValve, currently undergoing evaluation in the SAVVE pivotal study, aims to restore proper blood flow in the leg by functioning as a one-way valve when implanted into the femoral vein.
Having been founded in 1999, enVVeno Medical operates within the Manufacturing and Medical Devices industries. Notably, the company has recently secured a substantial $28.00M Post-IPO Equity investment as of 06 October 2023, with contributions from prominent investors such as Perceptive Advisors, L1 Capital, Kingdon Capital Management, Velan Capital, and Nantahala Capital Management.
Overall, enVVeno Medical's innovative approach and strong investor backing position the company as a key player in reshaping the standards of care for venous disease, reflecting promising potential for growth and impact within the medical device landscape.
